KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 40.91%.

  • Rigel Pharmaceuticals' EBIT Margin rose 155000.0% to 40.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.17%, marking a year-over-year increase of 361400.0%. This contributed to the annual value of 13.49% for FY2024, which is 310300.0% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EBIT Margin is 40.91%, which was up 155000.0% from 60.09% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBIT Margin ranged from a high of 60.09% in Q2 2025 and a low of 156.92% during Q1 2022
  • For the 5-year period, Rigel Pharmaceuticals' EBIT Margin averaged around 20.8%, with its median value being 15.87% (2023).
  • Data for Rigel Pharmaceuticals' EBIT Margin shows a peak YoY increase of 1090000bps (in 2022) and a maximum YoY decrease of -2084600bps (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' EBIT Margin stood at 104.94% in 2021, then skyrocketed by 104bps to 4.05% in 2022, then skyrocketed by 35bps to 5.49% in 2023, then surged by 426bps to 28.92% in 2024, then soared by 41bps to 40.91% in 2025.
  • Its EBIT Margin stands at 40.91% for Q3 2025, versus 60.09% for Q2 2025 and 23.95% for Q1 2025.